Fluvoxamine, 5-methyl-4′-trifluoromethylvalerophenone(E)-O-2-aminoethyloxime monomaleate, is one of several antidepressant agents known as selective serotonin reuptake inhibitors (SSRIS). The efficacy of fluvoxamine in depression has been reviewed in previous papers. 1, 2 The clinical pharmacokinetics of fluvoxamine were also described in a previous paper. 3 Negligible amounts of fluvoxamine are excreted unchanged in the human urine. Urinary fluvoxamine metabolites have been identified as consisting of at least 9 different compounds. About 65% of these metabolites resulted from oxidative demethylation of the aliphatic methoxyl group, and 15% of metabolites are formed by degradation at the primary amino group. Fluvoxamino acid is the main primary metabolite in humans. 4 Therefore, the monitoring of fluvoxamino acid on the drug interaction study of fluvoxamine will be able to detect slight changes of fluvoxamine metabolism by co-administered drug in healthy volunteers and/or patients.
Introduction
Fluvoxamine, 5-methyl-4′-trifluoromethylvalerophenone(E)-O-2-aminoethyloxime monomaleate, is one of several antidepressant agents known as selective serotonin reuptake inhibitors (SSRIS). The efficacy of fluvoxamine in depression has been reviewed in previous papers. 1, 2 The clinical pharmacokinetics of fluvoxamine were also described in a previous paper. 3 Negligible amounts of fluvoxamine are excreted unchanged in the human urine. Urinary fluvoxamine metabolites have been identified as consisting of at least 9 different compounds. About 65% of these metabolites resulted from oxidative demethylation of the aliphatic methoxyl group, and 15% of metabolites are formed by degradation at the primary amino group. Fluvoxamino acid is the main primary metabolite in humans. 4 A number of studies have examined the potential pharmacokinetic interaction of fluvoxamine with several drugs. 3 Increases in fluvoxamine plasma concentrations have been reported when it is prescribed in combination with clomipramine 5 and butyrophenone. 6 Several reports indicate that fluvoxamine increases the plasma concentration of concurrently administered tricyclic antidepressants, 7 benzodiazepines, 8 carbamazepine 9 and theophilline. 10 This suggests the possibility that other drugs may be involved in drug interactions when co-administered with fluvoxamine in clinical drug therapeutics. Therefore, further specific clinical studies for drug interaction with fluvoxamine should be performed for the purpose of avoiding adverse drug events. Fluvoxamine is extensively metabolized in the human liver by cytochrome p-450 1A2 to form the principal metabolite, fluvoxamino acid, and CYP appearances in metabolic pathways of the other metabolites have not been reported previously. Fluvoxamino acid accounts for 35% and the other metabolites less than 10% of all the metabolites in human urine.
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Therefore, the monitoring of fluvoxamino acid on the drug interaction study of fluvoxamine will be able to detect slight changes of fluvoxamine metabolism by co-administered drug in healthy volunteers and/or patients.
The pharmacokinetics of fluvoxamino acid in human has not yet been studied sufficiently.
Methods for the fluvoxamine by GC-MS, 12 HPLC with liquidliquid extraction of plasma samples [13] [14] [15] [16] [17] and HPLC with solidphase in-line extraction 18, 19 were described in previous papers. The liquid-liquid extraction methods are not completely satisfactory because they are time-consuming and require a tedious procedure. We have reported a simple extraction method of several drugs and their metabolites by using a solid phase extraction cartridge. [20] [21] [22] [23] However, an off-line solid phase extraction method for fluvoxamine has not been reported in previous papers. There is also no report for simultaneous determination of fluvoxamine and fluvoxamino acid in human plasma by HPLC.
The extraction of fluvoxamine and fluvoxamino acid in human plasma using a solid phase method has some problems: one is the simultaneous extraction from a complex mixture of both acidic and basic compounds. Therefore, a specific extraction method and an efficient chromatographic system without interfering peaks was needed 
High-Performance Liquid Chromatographic Determination of Fluvoxamine and Fluvoxamino Acid in Human Plasma
Tadashi OHKUBO,* † Ritsuko SHIMOYAMA,* Koichi OTANI,** Keizo YOSHIDA,*** Hisashi HIGUCHI,*** and Tetsuo SHIMIZU*** for development of a simultaneous determination method for fluvoxamine and fluvoxamino acid in human plasma by HPLC.
The present paper describes an HPLC method with ultraviolet detection combined with a simple and selective solid phase extraction method for the determination of fluvoxamine and fluvoxamino acid level in human plasma. The present method was applied to monitoring the steady-state concentrations (Css) of fluvoxamine and fluvoxamino acid in depressed Japanese patients.
Experimental

Reagents and materials
Fluvoxamine (Fig. 1a) was purchased from Sigma Chemical Co. (St. Louis, MO, USA) and fluvoxamino acid (Fig. 1b) was prepared in our laboratory according to the method explained in a previous paper. 4, 24 The purity of fluvoxamino acid was checked by HPLC; the mass spectrum supported the molecular weight of fluvoxamino acid. The moperone hydrochloride (Fig.  1c) was kindly donated by Daiichi Pharmaceutical (Tokyo, Japan). The Sep-Pak ® C18 cartridge was purchased from Waters Co. (Milford, MA, USA). The solvents used were of HPLC grade (Wako Pure Chemical Industries, Osaka, Japan). Other reagents and chemicals were purchased from Wako Pure Chemical Industries or Nacalai Tesque (Kyoto, Japan).
Preparation of standard solutions
The standard stock solutions were prepared by dissolving accurately weighed amounts of fluvoxamine, fluvoxamino acid and moperone (I.S.) in methanol to make 1 mg/mL of each concentration. These solutions could be stored stably in -20˚C for up to 6 months. The working solutions were prepared by diluting the stock solutions with methanol. The standard solution has been stable for over 6 months.
Instruments and chromatographic conditions
The apparatus used for HPLC was a Model 880-PU chromatography pump (Jasco, Tokyo, Japan) equipped with a Model 876-UV ultraviolet detector set at 254 nm wavelength, and a Rheodyne Model 7120 injector (Rheodyne, Cotati, CA, USA) with an effective volume of 100 µL. The HPLC columns (150 × 4.6 mm i.d.) used Grand Pack C18-5, Grand Pack C8-5, Grand Pack C4-5 and Grand Pack C2-5 of 5 µm particle size (MASIS, Owani, Japan); the end-cappings were carried out under the same condition for several stationary phases, for basic examination of suitable condition for chromatographic separation of fluvoxamine and fluvoxamino acid.
The analytical column used was a Grand Pack C4-5. The mobile phase consisted of 0.5% potassium dihydrogen phosphate (pH 2.5)-acetonitrile (75:25, v/v). A flow-rate of 1 mL/min was used at ambient temperature. Before mixing, the pH of 0.5% potassium dihydrogen phosphate was adjusted with 50% phosphoric acid and the mobile phase was degassed ultrasonically before use.
Assay procedure
Moperone (100 ng) in methanol (10 µL) was added to the plasma sample (1 mL) as an internal standard; then the plasma samples were diluted with 5 mL of water and the solution was briefly mixed. The mixture was applied to a Sep-Pak ® C18 cartridge that had been activated previously with 10 mL methanol and water. The cartridge was then washed with 5 mL of water and 5 mL of 30% methanol in water. The desired fraction was eluted with 5 mL of methanol. The eluate was evaporated to dryness in vacuum at 60˚C with a rotary evaporator (Iwaki, Tokyo, Japan). The residue was dissolved in a 50 µL of methanol and 50 µL of mobile phase, and then 60 µL of the reconstructed solution was injected on the HPLC apparatus.
Calibration graphs
Known amounts of fluvoxamine and fluvoxamino acid in the range of 25 -200 ng/mL were added to blank plasma sample. These plasma samples were treated in the same manner as previously described. Graphs were constructed of the peakheight ratio of fluvoxamine or fluvoxamino acid to I.S., plotted against the concentrations of fluvoxamine and fluvoxamino acid, respectively.
Recovery experiments
Each plasma sample was spiked by adding a known amount of fluvoxamine and fluvoxamino acid to drug-free plasma to obtain a total volume of 1.0 mL. These samples were extracted by the procedure described above. Control samples, which were several standard concentrations, were prepared by adding a known amount of fluvoxamine and fluvoxamino acid to 1.0 mL of methanol. These control samples were not extracted but were directly evaporated to dryness at 60˚C; then the residues were reconstituted with 50 µL of methanol and 50 µL of mobile phase. An external standard was added to all of the control samples instead of the internal standard before the samples were evaporated to dryness. The recovery was determined by comparison between solid-phase extractions with the nonextraction control.
Method validation
The accuracy of the method was determined by injection of fluvoxamine and fluvoxamino acid calibration samples and the four different quality control samples after extraction on six separate days. All calibration curves have a correlation value of at least 0.994. The accuracy was calculated as a percentage of the nominal concentration: Accuracy = (concentration observed/nominal concentration)×100%. The data used in the accuracy determination were also used for the calculation of the between-run percentage relative standard deviation (% R.S.D. = (S.D./mean)×100%). The within-run % R.S.D. resulted from analysis of six quality control samples at each concentration with injection on the same day.
Application to monitoring of fluvoxamine in patients
Twelve Japanese patients diagnosed as suffering from major depression disorder were treated with fluvoxamine (200 mg/day) for at least 14 days. The study protocol is approved by the Ethics Committees of Akita University School of Medicine, and all patients provided written informed consent to participate. Blood samples from patients were collected by venipuncture into heparinized blood collection tubes in the morning before breakfast (after 12 h) and before the morning dose (after 12 h). The blood was immediately centrifuged (1900 × g) at ambient temperature, and the plasma layer separated was stored at -40˚C until analysis.
Results
The effects of pH of the mobile phase on the retention factors (k′) value of fluvoxamine and fluvoxamino acid were studied using four kinds of stationary phases (Fig. 2) . The k′ value of fluvoxamine increased with pH in the range of 2.5 -6.5 with 0.5% KH2PO4:acetonitrile (75:25, v/v). However, the k′ value of fluvoxamino acid decreased with increasing pH. The decreasing ratios of k′ values for fluvoxamino acid on each stationary phase were proportional to the ordered alkyl chain length from C18 to C2 in the HPLC stationary phases. Low k′ values and insufficient resolution were seen on the C2 stationary phase. High k′ values and sufficient resolution were obtained on the C18, C8 and C4 stationary phase. Sharper chromatogram peaks and short retention times were obtained on the C4 stationary phase than on the C18 and C8 stationary phases. Also the smallest change in k′ value caused by change in pH of the mobile phase was shown on the C4 stationary phase. Such results suggest that C4 stationary phase has an advantage over the other stationary phases, because it is possible to avoid interference peaks from biological fluids by changing of pH in mobile phase without change of drugs chromatogram. Therefore, the C4 analytical column was used for analysis of fluvoxamine and fluvoxamino acid with moperone as an internal standard in human plasma. An efficient chromatographic system for the mutual separation of several other psychiatric drugs was obtained with the C4 analytical column using 0.5% KH2PO4 (pH 2. Table 2 . The intra-day assay variance was determined by analyzing 1 mL aliquots from four spiked plasma samples containing fluvoxamine at 25, 50, 100 and 200 mg/mL and fluvoxamino acid at 25, 50, 100 and 200 ng/mL, and by calculating their concentrations against a standard curve analyzed on the same day. The inter-day assay variance was determined by 1 mL aliquots of spiked plasma samples containing fluvoxamine and fluvoxamino acid at the same concentrations as above on 6 different days; the concentrations were calculated from the standard curves analyzed on the respective days. In both cases, the coefficients of variation for fluvoxamine and fluvoxamino acid were less than 7.6 and 8.2%. The recovery values for fluvoxamine and fluvoxamino acid were 94.0% -98.4%, and 96.5% -98.3%, respectively. The present method was applied to the monitoring of fluvoxamine and fluvoxamino acid in Japanese patients diagnosed as suffering from major depression disorder. Twelve clinical samples were assayed by the present method to determine the Css values of fluvoxamine and fluvoxamino acid in patients treated with oral doses of 200 mg of fluvoxamine each day. These results are shown in Table 3 .
Discussion
This paper describes a new method for determination of fluvoxamine and fluvoxamino acid by a solid-phase extraction coupled with HPLC. To our knowledge, our paper is the first to describe a simultaneous determination of fluvoxamine and fluvoxamino acid in human plasma. Our initial intent in the present study was to develop an efficient chromatographic system for the analysis of fluvoxamine and fluvoxamino acid. Suitable conditions for the efficient chromatography were examined in detail with four kinds of stationary phase: these were C18, C8, C4 and C2 analytical columns. The results of obtained k′ values on several columns at pH 2.5 suggest that the interaction between fluvoxamine or fluvoxamino acid and stationary phases mainly originated from the 4-(trifluoromethyl)phenyl-1-pentanone moiety (Figs. 1a and 1b) . This is due to the fact that the k′ values on C2 and C4 stationary phase at pH 2.5 were lower than the values on C8 and C18. However, k′ values of C8 and C18 columns were not directly proportional to carbon chain length on the stationary phase.
The k′ values of fluvoxamine and fluvoxamino acid were saturated on C8 stationary phase in C2, C4, C8 and C18 phases. On the other hand, k′ values on several columns at pH 6.5 suggested that the interaction between fluvoxamine and stationary phases increased to form free amino moieties on fluvoxamine (Fig. 1a) . However, interaction between fluvoxamino acid and stationary phases at pH 6.5 showed lower k′ values, because the ionization effect of carboxilic acid moiety on 1-pentanoic acid side chain is above the effect from the free amino moiety on 2-aminoethyloxime side chain from the viewpoint of lipophilic interaction. The peaks of fluvoxamine were broadened on C8 and C18 stationary phase at pH 6.5, because the lipophilic interaction of free amino moiety on fluvoxamine side chain may occur strongly on stationary phase. Fluvoxamino acid/ fluvoxamine ratio acid were obtained by C4 stationary phase column rather than C8 and C18 stationary phases at pH 6.5 of mobile phase. In our previous paper, 25 we described a case in point that the interference peaks from biological samples could be removed by alteration of the pH in mobile phase in HPLC method. The property of least change of k′ value according to pH alteration in mobile phase could be used for avoidance of interference peaks from plasma sample in chromatogram. This will be advantageous for determination of drugs in plasma sample by HPLC method. Therefore, we conclude that the C4 column was the most suitable stationary phase for simultaneous determination of fluvoxamine and fluvoxamino acid in plasma samples.
Several papers have described the HPLC method for the determination of fluvoxamine in plasma samples using a C8 stationary phase 14, [17] [18] [19] and C18 stationary phase. 13, 16 We think, from our present results, that the C8 and C18 stationary phase are not necessarily suitable for the simultaneous analysis of fluvoxamine and fluvoxamino acid, because great opposite changes of k′ values were observed at higher pH in mobile phase on C8 and C18 stationary phase. So we were able to establish separation of the fluvoxamine and fluvoxamino acid peaks from interference peaks with a mobile phase of 0.5% KH2PO4 (pH 2.5):acetonitrile (75:25, v/v) (Fig. 3) .
Previous reports of HPLC methods for fluvoxamine determination have some problems, because the methods are tedious and time-consuming. [13] [14] [15] [16] [17] Two papers have reported inline automatic solid phase extraction using C8 clean-up column. 18, 19 Our simple solid-phase extraction method, an efficient combination system in HPLC determination method, could remove interfering substances. [20] [21] [22] [23] Therefore, we have examined solid-phase extraction procedures in detail for the purpose of eliminating such endogenous interference peaks.
The extraction method of fluvoxamine, fluvoxamino acid and moperone (I.S.) in plasma was established using Sep-Pak ® C18 cartridge. Lower interference from endogenous components of plasma was achieved by using Sep-Pak ® C18. By testing several kinds of analytical columns, we found that a reversed-phase C4 (150 × 4.6 mm, i.d., 5 µm) column was the most efficient for separation of fluvoxamine, fluvoxamino acid and moperone from interfering endogenous substances in human plasma within suitable analytical times (Fig. 3) . In the present study, k′ values for several compounds besides fluvoxamine and fluvoxamino acid were experimentally determined by C18, C8, C4, and C2 columns with various pH values of mobile phases (Fig. 2) . Therefore, we were able to achieve exquisite selection of I.S. that have suitable retention times (14.8 min) between fluvoxamino acid (10.7 min) and fluvoxamine (21.7 min) on chromatogram.
Inter-day variations for fluvoxamine and fluvoxamino acid were in the range of 5.2 -7.6%, and 2.7 -8.2%, respectively (Table 2) .
These results indicated that the present method has satisfactory precision and is acceptable for monitoring of fluvoxamine and fluvoxamino acid in patient's plasma. The method was then applied to the determination of Css values of fluvoxamine and fluvoxamino acid in Japanese depression patients treated with oral doses of 200 mg of fluvoxamine per day for at least 14 days. These results are shown in Table 3 . The Css of fluvoxamine and fluvoxamino acid in twelve Japanese patients showed individual variations in the ranges of 48.3 -532.9 ng/mL and 35.6 -307.1 ng/mL, respectively. These suggested that there is a large inter-individual difference in bioavailability of fluvoxamine. Many previous papers described the effect of fluvoxamine on the pharmacokinetics of other drugs, which were metabolized by CYP2C19, 8 CYP3A4, [26] [27] [28] and CYP1A2. 28, 29 However, the specific isoenzymes involved in fluvoxamine metabolism have not been identified; nevertheless, in vitro and in vivo the drug potently inhibits the metabolism of substrates for CYP1A2. 29 We consider that our present HPLC method for the determination of fluvoxamine and fluvoxamino acid can be confidently applied to study in fluvoxamine for in vivo and in vitro drug metabolism.
